Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 4/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19029978 | 1.00 | GPR119 (0.44) | GPR119USP2SMN1; SMN2PIK3CAPIK3R1 | |
| SCHEMBL19029902 | 0.85 | IRAK4 (0.42) | SMN1; SMN2IRAK4 | |
| SCHEMBL19045086 | 0.85 | IRAK4 (0.46) | USP2SMN1; SMN2IRAK4 | |
| SCHEMBL19030303 | 0.85 | MAPT (0.46) | GPR119USP2SMN1; SMN2IRAK4HRH3 | |
| SCHEMBL19045085 | 0.84 | USP2 (0.40) | GPR119USP2SMN1; SMN2IRAK4HRH3 | |
| SCHEMBL23110742 | 0.84 | IRAK4 (0.40) | IRAK4 | |
| SCHEMBL19030064 | 0.81 | IRAK4 (0.47) | IRAK4 | |
| SCHEMBL20594546 | 0.81 | SMARCA2 (0.45) | IRAK4 | |
| SCHEMBL19030334 | 0.80 | IRAK4 (0.45) | SMN1; SMN2IRAK4 | |
| SCHEMBL31235945 | 0.79 | NR1H2 (0.53) | GPR119HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220332718-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | GENENTECH, INC. (US) | 2022-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332718-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK1, IRAK4, IRAK2 | GPR119 1226/4885USP2 2869/4885SMN1; SMN2 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.